Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.63 |
| ▸ | NPC1 | O15118 | 6/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.63 |
| ▸ | TP53 | P04637 | 3/20 | 0.63 |
| ▸ | PKM | P14618 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 8/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.59 |
| ▸ | LMNA | P02545 | 5/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | HPGD | P15428 | 3/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31325644 | 1.00 | RAB9A (0.63) | RAB9ANPC1SMN1; SMN2TP53PKM | |
| SCHEMBL24995946 | 0.85 | RAB9A (0.50) | RAB9ANPC1SMN1; SMN2TP53PKM | |
| SCHEMBL20715318 | 0.77 | RAB9A (1.00) | RAB9ANPC1SMN1; SMN2TP53PKM | |
| SCHEMBL20918168 | 0.74 | RAB9A (0.55) | RAB9ANPC1SMN1; SMN2TP53PKM | |
| SCHEMBL6654114 | 0.73 | ATM (0.52) | MAPTALDH1A1KMT2AKDM4EMEN1 | |
| SCHEMBL1853438 | 0.72 | RAB9A (0.64) | RAB9ANPC1SMN1; SMN2TP53MAPT | |
| SCHEMBL22717647 | 0.71 | GAA (0.59) | RAB9ANPC1SMN1; SMN2TP53MAPT | |
| SCHEMBL31325652 | 0.71 | GAA (0.59) | RAB9ANPC1SMN1; SMN2TP53MAPT | |
| SCHEMBL734714 | 0.70 | NPC1 (0.64) | RAB9ANPC1SMN1; SMN2TP53PKM | |
| SCHEMBL24997095 | 0.70 | RAF1 (0.43) | RAB9ANPC1SMN1; SMN2TP53PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230106899-A1 | METHODS OF TREATING CANCER | NOVARTIS PHARMA AG (CH) | 2023-04-06 | — | — | US | disclosed |
| US-20220227760-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2022-07-21 | — | — | US | disclosed |
| EP-3976584-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM Due, Inc. (US) | 2022-04-06 | — | — | EP | disclosed |
| WO-2020257621-A1 | METHODS OF TREATING CANCER | IFM DUE, INC. (US) | 2020-12-24 | — | — | WO | disclosed |
| WO-2020243519-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC. (US) | 2020-12-03 | — | — | WO | disclosed |
| WO-2020243519-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC. (US) | 2020-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220227760-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | RAB9A 876/4885NPC1 859/4885SMN1; SMN2 2298/4885 |
| US-20230106899-A1 | METHODS OF TREATING CANCER | STING1, CGAS, TBK1 | RAB9A 1457/4885NPC1 249/4885SMN1; SMN2 2644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.